Vnitr Lek 2013, 59(6):501-504

Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk

J. Widimský jr.
Centrum pro hypertenzi III. interní kliniky 1. lékařské fakulty UK a VFN v Praze, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Primary hyperaldosteronism (PH) is common cause of secondary hypertension with autonomous aldosterone overproduction by adrenal cortex with high plasma aldosterone, suppressed renin and high blood pressure. Patients with PH have compared to essential hypertension (EH) more frequent sublinical organ damage and higher cardiovascular risk (CV). Higher carotid IMT, arterial stiffness and microalbuminuria was found in PH. Early specific therapy of PH may lead to the regression of target organ damage and decrease of CV risk. Early diagnostic and therapeutic measures are very important due to high prevalence of PH.

Keywords: primary hyperaldosteronism; hypertension; cardiovascular risk

Received: April 14, 2013; Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk. Vnitr Lek. 2013;59(6):501-504.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrom. J Lab Clin Med 1955; 43: 317.
    2. Litynski M. Nadcisnienie tetnicze wyvolane guzami korowo-nad-nerczowymi. Pol Tyg Lek 1953; 8: 204-208.
    3. Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2008; 93: 3266-3281. Go to original source... Go to PubMed...
    4. Štrauch B, Zelinka T, Widimský J jr. et al. Prevalence of primary hyperaldosteronism in middle Europe region. J Human Hypertens 2003; 17: 349-352. Go to original source... Go to PubMed...
    5. Widimský J jr. Primární hyperaldosetronismus: epidemie anebo jen častá příčina sekundární hypertenze? Cor Vasa 2008; 50: 366-367.
    6. Rizzoni D, Paiardi S, Rodella L et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642. Go to original source... Go to PubMed...
    7. Holaj R, Zelinka T, Wichterle D et al. Increased intima-media thickness of the common artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-1457. Go to original source... Go to PubMed...
    8. Štrauch B, Petrák O, Wichterle D et al. Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison with Essential Hypertension. Am J Hypertens 2006; 19: 909-914. Go to original source... Go to PubMed...
    9. Widimsky J jr., Strauch B, Petrák O et al. Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney Blood Pressure Res 2012; 35: 529-533. Go to original source... Go to PubMed...
    10. Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534. Go to original source... Go to PubMed...
    11. Milliez P et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Col Cardiol 2005; 45: 1243-1248. Go to original source... Go to PubMed...
    12. Rossi GP, Bernini G, Caliumi C et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J Am Col Cardiol 2006; 48: 2293-2300. Go to original source... Go to PubMed...
    13. Rossi GP, Bernini G, Desideri G et al. PAPY Study Participants Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-238. Go to original source... Go to PubMed...
    14. Born-Frontsberg E, Reincke M, Rump LC et al. Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130. Go to original source... Go to PubMed...
    15. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85. Go to original source... Go to PubMed...
    16. Reincke M, Fischer E, Gerum S et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60: 618-624. Go to original source... Go to PubMed...
    17. Krug AW, Ehrhart-Bornstein M. Aldosterone and Metabolic Syndrome: Is Increased Aldosterone in Metabolic Syndrome Patients an Additional Risk Factor? Hypertension 2008; 51: 1252-1258. Go to original source... Go to PubMed...
    18. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783. Go to original source... Go to PubMed...
    19. Fallo F, Veglio F, Bertello C et al. Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459. Go to original source... Go to PubMed...
    20. Fallo F, Federspil G, Veglio F et al. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep 2007; 9: 106-111. Go to original source... Go to PubMed...
    21. Šomlóová Z, Widimský J jr., Rosa J et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens 2010; 24: 625-630. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.